Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15325966 | 0.90 | MAPT (0.66) | MAPTTHRBPOLBALDH1A1KDM4E | |
| SCHEMBL11356053 | 0.88 | MAPT (0.84) | MAPTTHRBPOLBUSP2TP53 | |
| SCHEMBL12468873 | 0.87 | MAPT (0.81) | MAPTTHRBPOLBALDH1A1USP2 | |
| SCHEMBL12469065 | 0.86 | MAPT (0.69) | MAPTTHRBPOLBALDH1A1USP2 | |
| SCHEMBL15324908 | 0.86 | MAPT (0.60) | MAPTTHRBPOLBALDH1A1KDM4E | |
| SCHEMBL12469777 | 0.86 | MAPT (0.71) | MAPTTHRBPOLBUSP2CA2 | |
| SCHEMBL11362002 | 0.86 | POLB (0.76) | MAPTTHRBPOLBUSP2CA2 | |
| SCHEMBL15324597 | 0.86 | MAPT (0.71) | MAPTTHRBPOLBUSP2CA2 | |
| SCHEMBL15323131 | 0.85 | MAPT (0.59) | MAPTTHRBPOLBALDH1A1KDM4E | |
| SCHEMBL12468669 | 0.85 | MAPT (0.60) | MAPTTHRBPOLBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296732-B2 | Substituted benzamides and their uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150072976-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | ARAVIVE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072976-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | NISCH, BTD, NAAA | MAPT 2582/4885THRB 2141/4885POLB 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.